Page 25 - Pharma Companies
Cipla urges govt to increase funds, ease policies for domestic pharma firms
In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health
 "Cipla urges govt to increase funds, ease policies for domestic pharma firms")
Growth in US business likely to boost Q1 revenues of pharma companies
According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY
 "Growth in US business likely to boost Q1 revenues of pharma companies")
Centre may get stricter to check overcharging of medicines by pharma cos
The idea is to cancel the licenses of manufacturers who do not deposit the demanded amount within the prescribed time limit given by the NPPA
 "Centre may get stricter to check overcharging of medicines by pharma cos")
Domestic-focused pharma companies gain spotlight with stable growth outlook
Those with high non-US revenue streams such as Torrent Pharma, Ipca Labs, Ajanta Pharma and a few multinationals remain well placed
 "Domestic-focused pharma companies gain spotlight with stable growth outlook")
US drag on pharma majors' margins in Q4; experts see R&D costs rising
While the US headwinds continue, domestic market sales have been positive and show signs of recovery after the implementation of the goods and services tax
 "US drag on pharma majors' margins in Q4; experts see R&D costs rising")
From Cipla to Glenmark, pharma companies' double-digit growth in doubt
Govt's proposed changes in pricing policy could play spoilsport
 "From Cipla to Glenmark, pharma companies' double-digit growth in doubt")
Eight Chinese pharma firms may get blacklisted over low quality materials
The notices were issued after a special inspection team of the Drug Controller General of India inspected the eight companies in China
Pharma companies' revenues seen growing at 9% over next 3 years: Crisil
Exports, which account for nearly 45 per cent of industry revenue, will see another year of a tepid one per cent growth in fiscal 2018
Revival of US generic sales not before FY19, say analysts
Sharp fall in Teva's June quarter earnings dash hopes of recovery for domestic pharma firms
 "Revival of US generic sales not before FY19, say analysts")
Pharma companies may report subdued performance in Q2 FY17: Report
The US remains mainstay for most companies, contributing 55-60 per cent of total exports
 "Pharma companies may report subdued performance in Q2 FY17: Report")
Pharma companies' profits will moderate in near term: CRISIL
According to CRISIL, exports of generic drugs to the US will slow down 300 basis points to 10-12% in the medium term
 "Pharma companies' profits will moderate in near term: CRISIL")
Earnings support expected for pharma
This will be a relief for the sector, which is battling regulatory pressures at home and in the US
 "Earnings support expected for pharma")